Figure 1
From: Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer
IGF-1R expression correlated with reduced sensitivity to chemotherapy in ovarian cancer cell lines. (A) Fifteen ovarian cancer cell lines were treated in triplicate with paclitaxel or cisplatin as indicated for 72 hours, and raw luminescent values were normalized to vehicle control cells. (B) Cell surface expression of IGF-1R and ErbB3 were assessed via quantitative flow cytometry across the ten ovarian cancer cell lines. (C) Cell line responsiveness to paclitaxel or cisplatin from A correlated to cell surface receptor expression from (B).
